Population testing for cancer predisposing BRCA1/BRCA2 mutations in the ashkenazi-jewish community: A randomized controlled trial

Journal of the National Cancer Institute

Volumn 107, Issue 1, 2015, Pages

  Manchanda, Ranjit ^a,b   Loggenberg, Kelly ^a   Sanderson, Saskia ^c   Burnell, Matthew ^a   Wardle, Jane ^a   Gessler, Sue ^a   Side, Lucy ^a   Balogun, Nyala ^a   Desai, Rakshit ^a   Kumar, Ajith ^d   Dorkins, Huw ^e   Wallis, Yvonne ^f   Chapman, Cyril ^f   Taylor, Rohan ^g   Jacobs, Chris ^h   Tomlinson, Ian ⁱ   McGuire, Alistair ^j   Beller, Uziel ^k   Menon, Usha ^a   Jacobs, Ian ^a,l  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e NORTHWICK PARK HOSPITAL   (United Kingdom)

^f BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^g ST GEORGE S HOSPITAL   (United Kingdom)

^h GUY S HOSPITAL   (United Kingdom)

ⁱ IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^j LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^k SHAARE ZEDEK MEDICAL CENTER   (Israel)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN;

ADULT; ANXIETY; ARTICLE; ASHKENAZI JEW; ASSESSMENT OF HUMANS; CANCER SCREENING; CONTROLLED STUDY; DEPRESSION; DISTRESS SYNDROME; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SCREENING; HEALTH ANXIETY; HEALTH ANXIETY INVENTORY; HIGH RISK POPULATION; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INCOME; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MULTIDIMENSIONAL IMPACT OF CANCER RISK ASSESSMENT QUESTIONNAIRE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SHORT FORM 12; AGED; COMPARATIVE STUDY; DECISION SUPPORT SYSTEM; EARLY DIAGNOSIS; FOUNDER EFFECT; GENETICS; HETEROZYGOTE; JEW; MENTAL STRESS; MIDDLE AGED; MUTATION; NEOPLASM; PROCEDURES; PSYCHOLOGY; RISK ASSESSMENT; RISK FACTOR; TIME;

ADULT; AGED; ANXIETY; BRCA1 PROTEIN; BRCA2 PROTEIN; DECISION SUPPORT TECHNIQUES; DEPRESSION; EARLY DETECTION OF CANCER; FEMALE; FOUNDER EFFECT; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; JEWS; MALE; MASS SCREENING; MIDDLE AGED; MUTATION; NEOPLASMS; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; STRESS, PSYCHOLOGICAL; TIME FACTORS;

EID: 84930452193     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju379     Document Type: Article

References (49)

1. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-1130.
2. Antoniou AC, Pharoah PD, Narod S, et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet. 2005;42(7):602-603.
3. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329-1333.
4. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336(20):1401-1408.
5. Finkelman BS, Rubinstein WS, Friedman S, et al. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol. 2012;30(12):1321-1328.
6. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80-87.
7. Evans DG, Baildam AD, Anderson E, et al. Risk reducing mastectomy: outcomes in 10 European centers. J Med Genet. 2009;46(4):254-258.
8. Nelson HD, Huffman LH, Fu R, et al. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U. S. Preventive Services Task Force. Ann Intern Med. 2005;143(5):362-379.
9. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055-1062.
10. Hartge P, Struewing JP, Wacholder S, et al. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet. 1999;64(4):963-970.
11. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks because of inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-646.
12. Moller P, Hagen AI, Apold J, et al. Genetic epidemiology of BRCA mutations-family history detects less than 50% of the mutation carriers. Eur J Cancer. 2007;43(11):1713-1717.
13. Sivell S, Iredale R, Gray J, et al. Cancer genetic risk assessment for individuals at risk of familial breast cancer. Cochrane Database Syst Rev. 2007(2):CD003721.
14. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370.
15. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Qualityof-life Assessment. J Clin Epidemiol. 1998;51(11):1171-1178.
16. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220-233.
17. Salkovskis PM, Rimes KA, Warwick HM, et al. The Health Anxiety Inventory: development and validation of scales for the measurement of health anxiety and hypochondriasis. Psychol Med. 2002;32(5):843-853.
18. Cella D, Hughes C, Peterman A, et al. A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol. 2002;21(6):564-572.
19. UKFOCSS. (2007) United Kingdom Familial Ovarian Cancer Screening Study. Institute for Women's Health.
20. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10(4):327-340.
21. Team RDC. (2011) R: A Language and Environment for Statistical Computing.
22. Schlich-Bakker KJ, ten Kroode HF, Ausems MG. A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Educ Couns. 2006;62(1):13-20.
23. Meiser B, Butow P, Friedlander M, et al. Psychological impact of genetic testing in women from high-risk breast cancer families. Eur J Cancer. 2002;38(15):2025-2031.
24. Smith KR, West JA, Croyle RT, et al. Familial context of genetic testing for cancer susceptibility: moderating effect of siblings' test results on psychological distress one to two weeks after BRCA1 mutation testing. Cancer Epidemiol Biomarkers Prev. 1999;8(4 Pt 2):385-392.
25. Metcalfe KA, Poll A, Llacuachaqui M, et al. Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2. Clin Genet. 2010;78(5):411-417.
26. Andrews L, Meiser B, Apicella C, et al. Psychological impact of genetic testing for breast cancer susceptibility in women of Ashkenazi Jewish background: a prospective study. Genet Test. 2004;8(3):240-247.
27. Friedman LC, Webb JA, Richards CS, et al. Psychological impact of receiving negative BRCA1 mutation test results in Ashkenazim. Genet Med. 1999;1(3):74-79.
28. Jenkinson C, Layte R. Development and testing of the UK SF-12 (short form health survey). J Health Serv Res Policy. 1997;2(1):14-18.
29. Utah DoH. 2002. Interpreting the SF12 2001 Utah Health Status Survey.
30. Beran TM, Stanton AL, Kwan L, et al. The trajectory of psychological impact in BRCA1/2 genetic testing: does time heal? Ann Behav Med. 2008;36(2):107-116.
31. Bahar AY, Taylor PJ, Andrews L, et al. The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U. S. population data. Cancer. 2001;92(2):440-445.
32. Metcalfe KA, Poll A, Royer R, et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol. 2010;28(3):387-391.
33. Levy-Lahad E, Gabai-Kapara E, Kaufman B, et al. Identification of BRCA1/BRCA2 carriers by screening in the healthy population and its implications. In: American Society of Clinical Oncology, Annual meeting. 2011. J Clin Oncol. 2011;29(suppl):abstr 1513.
34. Weitzel JN, Lagos VI, Cullinane CA, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA. 2007;297(23):2587-2595.
35. Hopper JL, Southey MC, Dite GS, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev. 1999;8(9):741-747.
36. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999;91(11):943-949.
37. Hirsh-Yechezkel G, Chetrit A, Lubin F, et al. Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel. Gynecol Oncol. 2003;89(3):494-498.
38. de Sanjose S, Leone M, Berez V, et al. Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int J Cancer. 2003;106(4):588-593.
39. Kang HH, Williams R, Leary J, et al. Evaluation of models to predict BRCA germline mutations. Br J Cancer. 2006;95(7):914-920.
40. Marroni F, Aretini P, D'Andrea E, et al. Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet. 2004;41(4):278-285.
41. Barcenas CH, Hosain GM, Arun B, et al. Assessing BRCA carrier probabilities in extended families. J Clin Oncol. 2006;24(3):354-360.
42. Antoniou AC, Hardy R, Walker L, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet. 2008;45(7):425-431.
43. Kerlikowske K, Smith-Bindman R, Ljung BM, et al. Evaluation of abnormal mammography results and palpable breast abnormalities. Ann Internal Med. 2003;139(4):274-284.
44. Singleton N, Bumpstead R, O'Brien M, et al. (2002) Psychiatric morbidity among adults living in private households, 2000.
45. Crawford JR, Henry JD, Crombie C, et al. Normative data for the HADS from a large non-clinical sample. Br J Clin Psychol. 2001;40(Pt 4):429-434.
46. Chatterjee N, Kalaylioglu Z, Shih JH, et al. Case-control and case-only designs with genotype and family history data: estimating relative risk, residual familial aggregation, and cumulative risk. Biometrics. 2006;62(1):36-48.
47. Chatterjee N, Shih J, Hartge P, et al. Association and aggregation analysis using kin-cohort designs with applications to genotype and family history data from the Washington Ashkenazi Study. Genet Epidemiol. 2001;21(2):123-138.
48. Chatterjee N, Wacholder S. A marginal likelihood approach for estimating penetrance from kin-cohort designs. Biometrics. 2001;57(1):245-252.
49. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol. 2008;26(10):1135-1145.